Castration-resistant Prostate Cancer

• CLINICAL_TRIALS trial_result · 2025-02-17
  Clinical Trial Update: Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

  This completed prospective multicenter Swiss registry study assesses the performance of 177Lu-PSMA-I&T radioligand therapy for metastatic ca…

• CLINICAL_TRIALS trial_result · 2025-02-14
  Clinical Trial Update: Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer [EARLY_Phase 1]

  A Phase 1 clinical trial update from Sichuan University reports safety, whole-body distribution, and radiation dosimetry data in patients wi…

• CLINICAL_TRIALS trial_result · 2025-02-13
  Clinical Trial Update: A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 1]

  AC176, an investigational therapy, in a Phase 1 study for metastatic castration-resistant prostate cancer has been terminated.

• CLINICAL_TRIALS trial_result · 2025-02-05
  Clinical Trial Update: Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer [NA]

  Completed single-center, single-arm study evaluating the safety and efficacy of the radiopharmaceutical 177Lu-LNC1011 in PSMA PET-positive m…

• CLINICAL_TRIALS trial_result · 2025-02-03
  Clinical Trial Update: Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 1]

  Phase 1 safety and immunogenicity results for JNJ-64041809, a live attenuated Listeria-based immunotherapy, in metastatic castration-resista…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-02-03
  Clinical Trial Update: A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1]

  The Phase 1 trial evaluating EPI-7386 in combination with abiraterone acetate plus prednisone or with apalutamide in metastatic castration-r…

• CLINICAL_TRIALS trial_result · 2025-02-03
  Clinical Trial Update: A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy [Phase 4]

  Completed Phase 4 clinical trial evaluating abiraterone acetate in metastatic castration-resistant prostate cancer patients who had a poor r…

• CLINICAL_TRIALS trial_result · 2025-01-29
  Clinical Trial Update: Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer [Phase 2]

  Phase II study evaluating olaparib, a PARP inhibitor, with intravenous ascorbate for castration-resistant prostate cancer; the trial is term…

• CLINICAL_TRIALS trial_result · 2025-01-24
  Clinical Trial Update: A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

  Phase 2 trial update evaluating SHR3162 with Apatinib or SHR3162 alone in metastatic castration-resistant prostate cancer has completed.

• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy [Phase 4]

  Phase 4 safety and efficacy results for enzalutamide in Indian patients with metastatic castration-resistant prostate cancer previously trea…

• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) [Phase 2]

  Phase 2 trial update of irofulven in metastatic castration-resistant prostate cancer patients previously treated with docetaxel, using a Dru…

• CLINICAL_TRIALS trial_result · 2025-01-23
  Clinical Trial Update: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer [Phase 1]

  A Phase 1 trial from the University of Michigan evaluates talazoparib in combination with belinostat in metastatic breast cancer, metastatic…

• CLINICAL_TRIALS trial_result · 2025-01-22
  Clinical Trial Update: Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer [Phase 1]

  A Phase 1 trial evaluated oral BIBF 1120 (nintedanib) in combination with docetaxel and prednisone in patients with hormone-refractory prost…

• CLINICAL_TRIALS trial_result · 2025-01-20
  Clinical Trial Update: Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide [Phase 2]

  This Phase 2 trial assesses pembrolizumab in patients with metastatic castration-resistant prostate cancer who were previously treated with …

• CLINICAL_TRIALS trial_result · 2025-01-13
  Clinical Trial Update: Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  Expanded access treatment with Lu-177-PNT2002 for adults with PSMA-positive metastatic castration-resistant prostate cancer, currently tempo…

• CLINICAL_TRIALS trial_result · 2025-01-08
  Clinical Trial Update: Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC) [Phase 2]

  Phase 2 study evaluating Radiometabolic Therapy with Lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer has completed.

• CLINICAL_TRIALS trial_result · 2025-01-01
  Clinical Trial Update: Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma [Phase 2]

  Phase 2 trial evaluating olaparib in castration-resistant prostate cancer was terminated; results have been posted.

• CLINICAL_TRIALS trial_result · 2024-12-13
  Clinical Trial Update: A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. [Phase 1]

  A Phase I/Ib trial of NZV930 alone and in combination with PDR001 and/or NIR178 in patients with advanced malignancies has been terminated.

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status [Phase 2]

  Phase 2 trial evaluating Radium-223 in asymptomatic metastatic castration-resistant prostate cancer patients on Abiraterone or Enzalutamide,…

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. [Phase 1, Phase 2]

  The clinical trial update reports termination of the Phase 1/2 study of ONCT-534 in metastatic castration-resistant prostate cancer, and res…

• CLINICAL_TRIALS trial_result · 2024-12-11
  Clinical Trial Update: 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]

  Phase 1/Phase 2 trial update for the radiopharmaceutical 177Lu-LNC1011 in metastatic castration-resistant prostate cancer. The current trial…

• CLINICAL_TRIALS trial_result · 2024-12-10
  Clinical Trial Update: Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]

  Phase 2 multicenter trial evaluating abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer; res…

• CLINICAL_TRIALS trial_result · 2024-11-22
  Clinical Trial Update: Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate Cancer [Phase 2]

  A Phase 2 biomarker-driven intermittent docetaxel trial in metastatic castration-resistant prostate cancer has been terminated.

• CLINICAL_TRIALS trial_result · 2024-11-21
  Clinical Trial Update: A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

  A registry-based study in Sweden evaluates overall survival and treatment duration in metastatic castration-resistant prostate cancer patien…

• CLINICAL_TRIALS trial_result · 2024-11-21
  Clinical Trial Update: A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients [Phase 1, Phase 2]

  This Clinical Trial Update reports on a completed Phase 1/2 study of MDV3100 (enzalutamide) in prostate cancer to evaluate safety, tolerabil…